The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Launching in 2022, its availability will be expanded to the global market
Forty-two per cent Indian patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described “confusion about what I was supposed to do next” as an important barrier to early and accurate diagnosis
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
The new facility will provide an important boost to vaccine capacity in Africa
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
Subscribe To Our Newsletter & Stay Updated
